On the sidelines of a high-level U.S. visit ABU DHABI, UAE, July 4, 2025 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, has announced a landmark partnership with the University of California, San Francisco (UCSF) and the Innovative Genomics Institute (IGI) to explore the establishment of the world's first-of-their-kind centres for genome surgery in Abu Dhabi and California. Formalised during a strategic visit to the United States,

BOSTON, July 4, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart Allostery platform-identified regulatory sites on proteins referred to as "natural hotspots," today announced the presentation of preclinical data from the Company's CARD11-BCL10-MALT1 (CBM) signalosome program at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025. The CB

BioDlink convenes a peer advisory event bringing together biotech CEOs, MNC leaders and researchers to discuss innovation and collaboration strategies Integrated one-stop technology platform helps innovative biotech companies launch life-saving therapies with greater speed, scale, and efficiency SUZHOU, China, July 4, 2025 /PRNewswire/ -- BioDlink, a leading global CDMO, hosted its 2025 Peer Advisory Board on June 26, 2025, spotlighting China's dynamic clinical trial and CDMO landscape as a glob

CHENGDU, China, July 4, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced the release of its inaugural sustainability report, aiming to present the company's philosophies and policies in environmental, social, and governance ("ESG") areas, as well as its sustainability practices and performance in the year of 2024, systematically addressing stakeholders' concerns. Dr. Jin Li, Chairman of the Board and CEO of HitGen Inc., commented:

BEIJING, China I July 03, 2025 I InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794. ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated

AstraZeneca's Imfinzi (durvalumab) has earned a green light from EU regulators as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC), expanding the PD-L1 inhibitor's reach in a setting where nearly half of patients experience disease recurrence despite current standard treatments.Specifically, the drug is approved for adults with resectable MIBC in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi monotherapy after radical cyste

The UK government has unveiled its latest plan to address the current shortcomings in the NHS and equip the health service with the tools and technologies it needs to deal with the country's changing demographic and ageing population. And while the Association of the British Pharmaceutical Industry (ABPI) welcomed a number of the proposed initiatives, it said the suggested overhaul "gets it right" in only a few key areas.Richard Torbett, chief executive of the ABPI, said "parts of the NHS 10 yea

Government entities overseeing medication access in New Zealand have been planning their adoption of AI assistants and tools to speed up processes and support decision-making. The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) and Pharmaceutical Management Agency (Pharmac) have been involved in the Ministry of Health's pilot of Microsoft Copilot, a smart, conversational AI-powered chatbot. Besides that, Medsafe is exploring the use of other AI tools "with the ability to man

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets DURHAM, N.C. and BEIJING, July 3, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical n

Only 4% of global drugs sales in 2030 will have patent protection. LanKS via Shutterstock. One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for a blow to their revenue streams, according to market analysis. A recent report by GlobalData projects that the share of global drug sales under patent protection will decline by 2030.  Only 4% of global drugs sales will have patent protection, compared to 12% and 6% in 2022 and 2024. Histo